BioMarin Pharmaceutical earnings date
BioMarin Pharmaceutical (BM8) Q3 2026 Earnings Report
DE:BM8 Q3 2026 EPS Results
- Actual EPS
- EUR 0.21
- Consensus EPS
- -EUR 0.04
- Beat/Miss
- Beat by +EUR 0.25
- One Year Ago EPS
- -EUR 0.14
DE:BM8 Q3 2026 Revenue Results
- Actual Revenue
- EUR 926.12M
- Expected Revenue
- EUR 924.31M
- Beat/Miss
- Beat by +EUR 1.81M
- YoY Revenue Growth
- +30.22%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/02/2026
- Time
- After Close
- Conference Call
- Monday, November 2, 2026
BioMarin Pharmaceutical's next earnings date is estimated for February 24, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive overall. BioMarin reported record quarterly revenue, broad-based product and patient growth, strong momentum for Galafold, Pombility and Opfolda, and VOXZOGO, ahead-of-schedule Amicus synergies, and substantial pipeline expansion. The principal negatives were lower full-year guidance caused by order timing and Middle East-related disruption, acquisition-related EPS charges, and uncertainty around competitive dynamics and early-stage pipeline programs. Management emphasized that the guidance reduction was not driven by patient demand and that the underlying business remained strong.
BioMarin updated full-year 2026 total revenue guidance to between $3.8 billion and $3.9 billion and non GAAP diluted earnings per share guidance to a range of $2.80 to $3.10; the update reflects approximately $70 million of orders expected between late Q4 and Q1 2027, with more than half of that $70 million being VOXZOGO, while the Inozyme acquisition is expected to reduce full year non GAAP diluted earnings per share by approximately $1.55 and the BMN-450 license agreement by approximately $0.32, including approximately $320 million of acquired IPR&D and ongoing operating expenses for Inozyme and approximately $83 million of primarily upfront acquired IPR&D expense and ongoing operating expenses for BMN-450. BioMarin continues to expect approximately $220 million of non-GAAP cost synergies to be realized fully in 2028, said the deal is accretive actually within 9 months, and is currently tracking to even calendar year accretion in 2026; it also expects VOXZOGO to continue to grow in 2027, with the hypochondroplasia launch contributing and Pombility and Opfolda revenue building into 2027 and beyond.
- Record Quarterly Revenue and Strong Top-Line GrowthThird-quarter revenue grew 32% year over year and surpassed $1 billion for the first time in BioMarin's history. Management characterized the underlying business as performing strongly.
- Metabolic Conditions Revenue GrowthMetabolic conditions revenue grew 44% year over year to $744 million, driven largely by the first full quarter of Galafold and Pombility and Opfolda. The number of patients on therapy increased across every marketed metabolic conditions brand.
- Galafold Growth and Patient ExpansionGalafold revenue was $152 million, 10% higher than the $138 million reported by Amicus for the third quarter of 2025. Patients treated increased approximately 13% year over year, with growth across established and newer markets.
- Pombility and Opfolda MomentumPombility and Opfolda revenue was $49 million, 58% higher than the $31 million reported by Amicus for the same period last year. Patients on therapy increased approximately 69% year over year, and the product became the market-share leader by patients on therapy in four European markets.
- Pombility and Opfolda Supply Support and Evidence BaseBioMarin released additional Pombility and Opfolda supply in certain European markets affected by supply constraints for other Pompe therapies, helping patients switch without treatment interruption. The company also highlighted five-year PROPEL extension data showing maintained motor function, relatively stable pulmonary function, sustained reductions in creatine kinase, and no new safety signals.
- VOXZOGO Patient Growth and International ExpansionVOXZOGO revenue grew 12% year over year to $245 million, while the number of children treated globally increased approximately 17%. More than 75% of third-quarter revenue came from outside the United States, and BioMarin received approval to treat children with achondroplasia in three additional international markets.
- VOXZOGO Retention and Clinical EvidenceApproximately 85% of U.S. children remained on VOXZOGO at the end of September, and the pace of switching trended downward each month during the third quarter. More than 5,000 infants and children in 58 countries have been treated, supported by a growing body of long-term safety and efficacy data.
- Hypochondroplasia Launch PreparationBioMarin announced May 30, 2027 as the PDUFA date for VOXZOGO in hypochondroplasia, where it could become the first targeted therapy approved for the indication and potentially BioMarin's seventh first-in-disease medicine. The estimated global total addressable population is approximately 14,000 children.
- Hypochondroplasia Phase 3 and Commercial ReadinessThe company reported statistically significant improvements in growth velocity, height, and arm span in the first full Phase 3 results. Launch preparations include sharing the clinical evidence, increasing diagnosis and patient identification, educating more than 1,200 U.S. pediatric endocrinologists and geneticists, and engaging payers to support rapid access.
- Palynziq and Vimizim PerformancePalynziq patients on therapy increased 9% year over year, led by the U.S. adolescent launch, while revenue grew 2% as U.S. order timing normalized after a strong second quarter. Vimizim revenue grew 18% year over year, benefiting from orders outside the United States.
- New Clinical Pipeline AdditionsBioMarin added four new assets to its pipeline in 2026: BMN-450, BMN-440, BMN-34, and BMN-28. Management said the programs span preclinical through Phase 3 development and reflect five business-development deals completed in two years.
- BMN-450 Fabry OpportunityBMN-450 is a Phase 1/2 investigational long-acting enzyme replacement therapy for Fabry disease with the potential to become the first subcutaneous ERT in the space. It is intended to reduce treatment burden, may address a broader patient population than Galafold, received FDA orphan drug designation, and demonstrated differentiated preclinical efficacy across renal function, vascular health, and peripheral nervous system outcomes.
- BMN-440 Hypophosphatasia OpportunityBMN-440, added through the Inozyme acquisition, is an oral substrate-reduction therapy in a Phase 1/2a study for hypophosphatasia. In a mouse model, it reduced inorganic pyrophosphate, normalized the phosphate-to-pyrophosphate ratio, and improved bone mineralization, muscle strength, and mobility measures. Human data are expected in 2027.
- Amicus Integration and Cost SynergiesAmicus integration was described as progressing ahead of schedule. BioMarin said the deal is now expected to become accretive within nine months, with the company tracking toward even calendar-year accretion in 2026. The company continues to expect approximately $220 million of non-GAAP cost synergies to be fully realized in 2028.
- Continued Investment in Future GrowthManagement said it will continue investing in VOXZOGO, including new-market launches and deeper penetration in international markets, and remain focused on clinical-stage business-development opportunities aligned with its genetics, regulatory, manufacturing, and commercialization capabilities.
- Expected VOXZOGO Growth in 2027Management expects VOXZOGO to continue growing in 2027, supported by the potential hypochondroplasia launch, international expansion, deeper penetration in existing markets, continued exclusivity for children under two with achondroplasia, and potential switching opportunities.
DE:BM8 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 24, 2027 | 2026 (Q4) | 0.74- | -0.22 | ― | ― |
| Nov 02, 2026 | 2026 (Q3) | -0.040.21 | -0.14 | 243.75% (+0.35) | |
| Aug 06, 2026 | 2026 (Q2) | 0.861.08 | 1.11 | -2.44% (-0.03) | |
| May 04, 2026 | 2026 (Q1) | 0.630.69 | 0.86 | -20.00% (-0.17) | |
| Feb 23, 2026 | 2025 (Q4) | 0.15-0.22 | 0.58 | -137.50% (-0.80) | |
| Oct 27, 2025 | 2025 (Q3) | -0.25-0.14 | 0.5 | -129.09% (-0.64) | |
| Aug 04, 2025 | 2025 (Q2) | 0.781.11 | 0.5 | 123.64% (+0.61) | |
| May 01, 2025 | 2025 (Q1) | 0.650.86 | 0.42 | 106.52% (+0.44) | |
| Feb 19, 2025 | 2024 (Q4) | 0.480.58 | 0.1 | 481.82% (+0.48) | |
| Oct 29, 2024 | 2024 (Q3) | 0.480.50 | 0.19 | 161.90% (+0.31) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


